

Top Companion Diagnostic Companies: Competitive Analysis 2013-2023

<https://marketpublishers.com/r/TEA190D8F77EN.html>

Date: January 2013

Pages: 157

Price: US\$ 2,401.00 (Single User License)

ID: TEA190D8F77EN

Abstracts

A myriad of pharmaceutical and diagnostic companies are now entering the highly attractive market of companion diagnostics, many of them entering into collaborations for developing a combination product. Apart from the well-known pharmaceutical and diagnostic companies, some small, niche-companies are also focusing on companion diagnostic development. At present, competition is largely dependent on the ability to collaborate with biotechnology and pharmaceutical companies to develop and commercialise these tests for their therapeutic drugs and drug candidates. The number of partnerships between the two industries will keep expanding as most pharmaceutical companies do not have an in-house diagnostic capability for either the development of a companion diagnostic or the commercialisation of the test once the drug is approved.

Top Companion Diagnostic Companies: Competitive Analysis 2013-2023 analyses the top 12 companies involved in the companion diagnostics market. This report also provides our sales forecasts, market share analyses, discussions of technological developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 125 tables and figures included. The result is a comprehensive market, and industry-centred study, with detailed analyses and informed opinion to benefit your work. Visiongain has determined that the value of the global companion diagnostics market will reach \$19.3bn in 2023.

What makes this report unique?

Visiongain consulted widely with industry experts and full transcripts from these exclusive interviews are included in the report. As such, our reports have a unique blend of primary and secondary sources providing informed opinion. The report provides insight into key drivers and restraints facing the industry, as well as identifying leading

companies. The report also provides a unique blend of qualitative analysis combined with extensive quantitative data including global, submarket and national markets forecasts from 2012-2023 - all highlighting key business opportunities.

Why you should buy Top Companion Diagnostic Companies: Competitive Analysis 2013-2023

137 pages of comprehensive analysis

1 Exclusive Visiongain interviews with experts from-
Myriad Genetics

125 tables, charts, and graphs

Companion diagnostic market forecast between 2012-2023

2 companion diagnostic submarket forecasts from 2012-2023
Theranostics

Other companion diagnostics

A SWOT analysis

Several leading companies identified and 12 profiled -
Roche, Dako, QIAGEN, Abbott, Life Technologies, LabCorp, Genomic
Health, MDxHealth, bioMerieux, Johnson and Johnson, Siemens and
Myriad Genetics

You can order this report today

Gain an understanding of the overall companion diagnostics market and the leading companies operating in this market by ordering Top Companion Diagnostic Companies: Competitive Analysis 2013-2023.

Contents

1. EXECUTIVE SUMMARY

- 1.1 Leading Companion Diagnostic Companies: Overview of Findings
- 1.2 Chapter Outline
- 1.3 Research and Analysis Methods
- 1.4 Aims, Scope and Format of the Report
- 1.5 Glossary of Terms Related to the Report

2. INTRODUCTION TO COMPANION DIAGNOSTICS

- 2.1 Changing Paradigms of Treatment
- 2.2 What is Personalised Medicine?
- 2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
 - 2.3.1 What are In Vitro Diagnostic (IVD) Tests?
 - 2.3.2 How IVDs Help Provide Personalised Treatment
- 2.4 Companion Diagnostics: Tools for Personalised Medicine
 - 2.4.1 Theranostics: A Subset of Companion Diagnostics
- 2.5 Biomarkers to Companion Diagnostics
 - 2.5.1 Advancements in Biomarker Discovery
 - 2.5.2 Genomics
 - 2.5.3 Pharmacogenomics
 - 2.5.4 Genomic Biomarkers in Oncology
 - 2.5.5 Proteomics
 - 2.5.6 Metabolomics
- 2.6 Development of Companion Diagnostics
- 2.7 Regulations in the Companion Diagnostics Market
 - 2.7.1 FDA's Draft Guidance on Companion Diagnostics

3. THE WORLD COMPANION DIAGNOSTICS MARKET, 2011-2023

- 3.1 Scope and Limitations
- 3.2 Total Companion Diagnostics Market was Worth \$1.6bn in 2011
- 3.3 Theranostics Constituted 34.3% of the Companion Diagnostics Market and 1.2% of the IVD Market in 2011
- 3.4 Companion Diagnostics is One of the Fastest Growing Segments in the IVD Market
- 3.5 Sales Forecast for the Global Companion Diagnostics Market, 2011-2016

- 3.5.1 Positive Reimbursement Outlook in the Companion Diagnostics Market
- 3.6 Sale Forecast for the Global Companion Diagnostics Market, 2016-2023

4. THERANOSTICS MARKET, 2011-2013

- 4.1 Theranostics Market Forecast
 - 4.1.1 Theranostics will Dominate the Companion Diagnostics Market
 - 4.1.2 Oncology Remains the Largest Clinical Area in the Market
 - 4.1.2.1 Other Clinical Areas will Increase Their Market Share

5. COMPETITIVE LANDSCAPE AND CURRENT BUSINESS MODELS, 2012

- 5.1 Competitive Landscape in 2012
- 5.2 Stakeholders in the Companion Diagnostics Market
 - 5.2.1 Regulatory Authorities
 - 5.2.2 Testing Laboratories
 - 5.2.3 Physicians and Patients
 - 5.2.4 Payers
- 5.3 Business Models for the Development of Companion Diagnostics

6. THE LEADING NORTH AMERICAN COMPANION DIAGNOSTIC COMPANIES, 2012

- 6.1 Abbott Laboratories, Inc.
 - 6.1.1 Sales and Recent Performance Analysis, 2011
 - 6.1.2 Abbott: Medical Devices and Diagnostics
 - 6.1.2.1 Companion Diagnostics
 - 6.1.2.1.1 Recent M&A Activity and Strategic Collaborations
 - 6.1.2.1.1.1 Collaboration with GSK
 - 6.1.2.1.1.2 Collaboration with Merck
 - 6.1.2.1.1.3 Acquisition of STARLIMS Technologies
 - 6.1.2.1.1.4 Acquisition of Ibis Biosciences, Inc.
 - 6.1.3 Plans to Separate into Two Publicly Traded Companies
- 6.2 Myriad Genetics
 - 6.2.1 Sales and Recent Performance Analysis, 2011
 - 6.2.2 R&D Capabilities
 - 6.2.3 Companion Diagnostics
 - 6.2.3.1 Myriad RBM
 - 6.2.3.2 M&A Activity and Recent Partnerships

- 6.2.3.2.1 Agreement with BioMarin Pharmaceutical
- 6.2.3.2.2 Acquisition of Myriad RBM
- 6.2.3.2.3 Strategic Debt Investment in Crescendo Bioscience
- 6.2.3.2.4 Agreement with Cephalon
- 6.2.3.2.5 Agreement with PharmaMar

6.3 Genomic Health

- 6.3.1 Sales and Recent Performance Analysis, 2011
- 6.3.2 R&D Capabilities
 - 6.3.2.1 TAILORx Clinical Trial
 - 6.3.2.2 RxPonder Trial
 - 6.3.2.3 Partnership with OncoMed

6.4 Johnson and Johnson

- 6.4.1 Sales and Recent Performance Analysis, 2011
- 6.4.2 Medical Devices and Diagnostics
 - 6.4.2.1 Companion Diagnostics
 - 6.4.2.1.1 Companion Diagnostics Center of Excellence
 - 6.4.2.1.2 Collaboration with Tianjin Medical University Cancer Institute and Hospital
 - 6.4.2.1.3 Partnership with Massachusetts General Hospital
 - 6.4.2.1.4 Partnership with Biocartis

6.5 Laboratory Corporation of America (LabCorp)

- 6.5.1 Sales and Recent Performance Analysis, 2011
- 6.5.2 Companion Diagnostics
- 6.5.3 Recent M&A Activity and Other Key Developments
 - 6.5.3.1 Agreement with Medco Health Sciences
 - 6.5.3.2 Acquisition of Monogram Biosciences
 - 6.5.3.3 Non-Exclusive License Agreement with Merck
 - 6.5.3.4 Acquisition of Genzyme Genetics
 - 6.5.3.5 Partnership with ARCA Biopharma

6.6 Life Technologies

- 6.6.1 Sales and Recent Performance Analysis, 2011
- 6.6.2 Companion Diagnostics
 - 6.6.2.1 Recent Companion Diagnostics Partnerships and Agreements
 - 6.6.2.1.1 Acquisition of Navigenics
 - 6.6.2.1.2 Partnership with Bristol-Myers Squibb
 - 6.6.2.1.3 Acquisition of Compendia Bioscience
 - 6.6.2.1.4 Partnership with GSK

7. THE LEADING EUROPEAN COMPANION DIAGNOSTIC COMPANIES, 2012

7.1 QIAGEN

7.1.1 Sales and Recent Performance Analysis, 2011

7.1.1.1 Continued Expansion in the Emerging Markets

7.1.2 R&D Capabilities

7.1.2.1 More than 15 Projects to Co-Develop and Market Companion Diagnostics

7.1.3 Provider of Choice for Molecular Companion Diagnostics

7.1.4 Recent M&A Activity and Other Key Developments

7.1.4.1 Acquisition of Cellestis Ltd.

7.1.4.2 Acquisition of Ipsogen

7.1.4.3 Partnership with Pfizer

7.1.4.4 Partnership with Eli Lilly

7.1.4.5 Acquisition of SABiosciences Corporation

7.1.4.6 Acquisition of DxS Ltd (Now QIAGEN Manchester)

7.1.4.7 Acquisition of Explera s.r.l

7.2 Roche

7.2.1 Sales and Recent Performance Analysis, 2011

7.2.2 Roche Diagnostics

7.2.3 R&D Capabilities

7.2.4 Growing Portfolio of Companion Diagnostics

7.2.4.1 Exploring Strategies in the Neurological Sector

7.3 Dako (Agilent Technologies)

7.3.1 Sales and Recent Performance Analysis, 2011

7.3.2 Companion Diagnostics

7.3.3 M&A Activity and Other Key Developments

7.4 bioMerieux

7.4.1 Sales and Recent Performance Analysis, 2011

7.4.2 Companion Diagnostics

7.4.2.1 Recent M&A Activity and Collaborations

7.4.2.1.1 Partnership with GSK

7.4.2.1.2 Partnership with Ipsen

7.4.2.1.3 Partnership with Institute Merieux and Institute Pasteur

7.4.2.1.4 Collaboration with Hospices Civils de Lyon

7.4.2.1.5 Acquisition of ARGENE

7.4.2.1.6 Equity Interest in Knome, Inc.

7.5 Siemens

7.5.1 Sales and Recent Performance, 2011

7.5.2 Siemens Healthcare

7.5.2.1 Siemens Diagnostics

7.5.2.2 Outperforming the Market

7.5.2.3 Companion Diagnostics

7.5.2.3.1 Partnership with ViiV Healthcare

7.5.2.3.2 Partnership with Tocagen

7.6 MDx Health

7.6.1 Sales and Recent Performance Analysis, 2011

7.6.2 R&D Capabilities

7.6.3 Companion Diagnostics

7.6.3.1 PharmacoMDx

7.6.3.2 PredictMDx for Brain Cancer

7.6.3.3 PredictMDx for Colon Cancer

7.6.3.4 Partnership with GSK

7.7 Other Recent Companion Diagnostics Partnerships

7.8 Other Companies in the Companion Diagnostics Market

8. SWOT ANALYSIS OF THE COMPANION DIAGNOSTICS MARKET

8.1 Introduction

8.2 Strengths

8.2.1 Minimising Harm

8.2.2 Streamlining Clinical Trials

8.2.3 Increasing Compliance

8.2.4 Positive Reimbursement Outlook in Key Regional Markets

8.3 Opportunities

8.3.1 Fast-Growing Emerging Markets

8.3.1.1 China's 12th Five Year Plan (2010-2015)

8.3.2 Growing Number of Partnerships Between Pharma and Diagnostics Companies

8.3.3 New Biomarkers in Development

8.3.4 Companies Are Exploring New Clinical Areas for Companion Diagnostics

8.4 Weaknesses

8.4.1 Perceived Lower Revenues

8.4.2 Lack of Clear Regulatory Guidelines

8.4.3 Need for Industry Wide Value-Based Pricing Model for Diagnostics

8.5 Threats

8.5.1 Poor Economic Conditions in Certain Key Regional Markets May Limit Growth in the Companion Diagnostics Market

8.5.2 Complex Business Models Could Limit Growth

9. EXPERT OPINION

9.1 Dr. Peter Meldrum, President and CEO, Myriad Genetics Inc.

9.1.1 The Companion Diagnostics Market

9.1.2 Companion Diagnostic Regulations

9.1.3 Myriad's Competitive Advantage in the Companion Diagnostics Market

9.1.4 Presence in the Emerging Markets

9.1.5 Perspective on the Future of the Companion Diagnostics Market

10. CONCLUSIONS

10.1 Overview

10.2 Growing Number of Companies Entering the Companion Diagnostics Market

10.3 Roche: A One Stop Shop for Companion Diagnostics

10.4 Commercial Drivers of the Companion Diagnostics Market

10.5 Emerging Technologies that Will Help Drive the Companion Diagnostics Market Forward

10.6 Future Outlook and Concluding Remarks

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List Of Tables

LIST OF TABLES

Table 2.1 Differences between Traditional & Personalised Medicine, 2012

Table 2.2 Technologies and Platforms for Biomarker Research, 2012

Table 2.3 Examples of Clinically Relevant Cancer Biomarkers, 2012

Table 3.1 Global IVD Market: Sales (\$bn) and Market Share (%), 2011

Table 3.2 Global Companion Diagnostics Market: Revenue (\$bn) and Market Share (%) by Sector, 2011

Table 3.3 Global Companion Diagnostics Market Forecast: Revenues (\$bn), 2011-2016

Table 3.4 Global Companion Diagnostics Market Forecast: Revenues (\$bn), 2016-2023

Table 4.1 Theranostics Market Share (%) in the Companion Diagnostics Market, 2011, 2016 & 2023

Table 6.1 Abbott: Revenues (\$bn) and Shares (%) by Region, 2011

Table 6.2 Abbott: Revenues (\$bn) and Shares (%) by Sector, 2011

Table 6.3 Abbott Medical Devices and Diagnostics: Revenues (\$bn) and Shares (%) by Sector, 2011

Table 6.4 Myriad: Revenue (\$m) and Shares (%) by Sector, 2011

Table 6.5 Myriad Molecular Diagnostics: Revenue (\$m) and Shares (%) by Product, 2011

Table 6.6 Myriad Molecular Diagnostics: Revenue (\$m) and Share (%) by Sector, 2011

Table 6.7 Myriad: Biomarker Product Portfolio, 2012

Table 6.8 Myriad: List of Available Companion Diagnostics, 2012

Table 6.9 Genomic Health: Revenue (\$m) and Shares (%) by Reporting Segment, 2011

Table 6.10 Genomic Health: R&D Expense (\$m) and R&D Expense as a Percentage of Sales (%), 2011

Table 6.11 Johnson and Johnson: Revenues (\$bn) and Shares (%) by Sector, 2011

Table 6.12 Johnson and Johnson: Revenues (\$bn) and Shares (%) by Region, 2011

Table 6.13 J&J Medical Devices and Diagnostics: Revenue (\$bn) and Shares (%) by Brand, 2011

Table 6.14 J&J Medical Devices and Diagnostics: Revenue (\$bn) and Shares (%) by Region, 2011

Table 6.15 LabCorp: Revenues (\$bn) and Shares (%) by Reporting Segment, 2011

Table 6.16 Selected List of LabCorp's Menu of Companion Diagnostics, 2012

Table 6.17 LabCorp: Recently Launched Companion Diagnostics, 2012

Table 6.18 Life Technologies: Revenue (\$bn) and Shares (%) by Sector, 2011

Table 7.1 QIAGEN: Revenue (\$m) and Shares (%) by Customer Class, 2011

Table 7.2 QIAGEN: Revenue (\$m) and Shares (%) by Region, 2011

Table 7.3 QIAGEN: Selected List of Co-development Projects in the Pipeline, 2012

Table 7.4 QIAGEN: Marketed Companion Diagnostics, 2012

Table 7.5 QIAGEN: List of Recent M&A Activity, 2011

Table 7.6 Roche: Revenue (\$bn) and Shares (%) by Sector, 2011

Table 7.7 Roche Diagnostics: Revenue (\$bn) and Shares (%), by Region 2011

Table 7.8 Roche Diagnostics: Revenue (\$bn) and Share (%) by Sector, 2011

Table 7.9 Roche Diagnostics: Key Diagnostic Products Recently Launched

Table 7.10 Roche Diagnostics: List of Marketed Companion Diagnostics, 2012

Table 7.11 Roche Diagnostics: List of Selected Products with an In-house Companion Diagnostic Drug Program

Table 7.12 Dako: Revenue (\$bn) and Shares (%) by Sector, 2011

Table 7.13 Dako: Revenues (\$bn) and Shares (%) by Region, 2011

Table 7.14 Dako: List of Marketed Companion Diagnostics, 2012

Table 7.15 bioMerieux: Revenue (\$m) and Shares (%) by Sector, 2011

Table 7.16 bioMerieux: Clinical Applications Revenue (\$m) and Shares (%) by Sector, 2011

Table 7.17 Siemens: Revenues (\$bn) and Shares (%) by Sector, 2011

Table 7.18 Siemens: Revenue (\$bn) and Shares (%) by Region, 2011

Table 7.19 Siemens Healthcare: Revenue (\$bn) and Shares (%) by Region, 2011

Table 7.20 Siemens Diagnostics: Ranking (#) by Sector, 2011

Table 7.21 MDxHealth: Revenue (\$m) and Shares (%) by Reporting Segment, 2011

Table 7.22 MDxHealth: Companion Diagnostics Pipeline, 2012

Table 7.23 List of Other Recent Companion Diagnostics Partnerships

Table 7.24 List of Other Companies in the Companion Diagnostics Market, 2012

Table 8.1 SWOT Analysis of the Companion Diagnostics Market, 2013-2023

Table 8.2 Drugs Metabolised by CYP450: 2C19 and 2D6, 2011

Table 10.1 Projected Total Companion Diagnostics Market Size (\$bn) in 2011, 2016, 2018 and 2023

List Of Figures

LIST OF FIGURES

Figure 2.1 The Pillars of Personalised Medicine

Figure 2.2 Type of Companion Diagnostics on the Basis of Purpose/Use, 2012

Figure 2.3 Development of Biomarkers into Companion Diagnostics, 2012

Figure 3.1 Global Companion Diagnostics Market Share (%) in the IVD Market, 2011

Figure 3.2 Global Companion Diagnostics Market: Revenue (\$bn) by Sector, 2011

Figure 3.3 Global Companion Diagnostics Market: Market Shares (%) by Sector, 2011

Figure 3.4 Companion Diagnostics Market Shares (%) by Sector in the IVD Market, 2011

Figure 3.5 Global Companion Diagnostics Market Forecast: Market Size (\$bn), 2011-2016

Figure 3.6 Global Companion Diagnostics Market Forecast: Market Size (\$bn), 2016-2023

Figure 4.1 Theranostics and Other Companion Diagnostics Markets: Market Sizes (\$bn), 2011-2023

Figure 4.2 World Theranostics and Other Companion Diagnostics Market Forecast: CAGR (%), 2011-2023

Figure 4.3 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2016

Figure 4.4 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2023

Figure 5.1 Stakeholders in the Companion Diagnostics Market, 2012

Figure 5.2 Current Business Models for the Development of Companion Diagnostics, 2012

Figure 6.1 Abbott Historical Performance: Revenue (\$bn), Net Income (\$bn), Profit Margin (%), 2007-2011

Figure 6.2 Abbott: Revenues (\$bn) by Region, 2011

Figure 6.3 Abbott: Revenue Shares (%) by Region, 2011

Figure 6.4 Abbott: Revenues (\$bn) by Sector, 2011

Figure 6.5 Abbott: Revenue Shares (%) by Sector, 2011

Figure 6.6 Abbott Medical Devices and Diagnostics: Revenues (\$bn) by Sector, 2011

Figure 6.7 Abbott Medical Devices and Diagnostics: Revenue Shares (%) by Sector, 2011

Figure 6.8 Abbott Diagnostics: Historical Margin (%) Improvement, 2007-2011

Figure 6.9 Myriad: Historical Net Revenues (\$m), 2005-2011

Figure 6.10 Myriad: Revenue Shares (%) by Sector, 2011

Figure 6.11 Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2011

Figure 6.12 Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2011

Figure 6.13 Myriad: Historical R&D Investments (\$m), 2007-2011

Figure 6.14 Genomic Health: Historical Revenues (\$m) and Net Income (\$m), 2007-2011

Figure 6.15 Genomic Health: Revenue Shares (%) by Reporting Segment, 2011

Figure 6.16 Genomic Health: Historical R&D Expense (\$m) and R&D as a Percentage of Net Sales (%), 2007-2011

Figure 6.17 Johnson and Johnson: Historical Revenue (\$bn), Net Income (\$bn) and Profit Margin (%), 2011

Figure 6.18 Johnson and Johnson: Revenues (\$bn) by Sector, 2011

Figure 6.19 Johnson and Johnson: Revenue Shares (%) by Sector, 2011

Figure 6.20 Johnson and Johnson: Revenue Shares (%) by Region, 2011

Figure 6.21 J&J Medical Devices & Diagnostics: Historical Revenues (\$bn), 2006-2011

Figure 6.22 J&J Medical Devices and Diagnostics: Revenues (\$bn) by Brand, 2011

Figure 6.23 J&J Medical Devices and Diagnostics: Revenue Shares (%) by Brand, 2011

Figure 6.24 J&J Medical Devices and Diagnostics: Revenue Shares (%) by Region, 2011

Figure 6.25 LabCorp: Historical Revenue (\$bn), Net Income (\$bn) and Profit Margin (%), 2007-2011

Figure 6.26 LabCorp: Revenues (\$bn) by Reporting Segment, 2011

Figure 6.27 LabCorp: Revenue Shares (%) by Reporting Segment, 2011

Figure 6.28 Life Technologies: Historical Revenue (\$bn), 2007-2011

Figure 6.29 Life Technologies: Revenue (\$bn) by Sector, 2011

Figure 6.30 Life Technologies: Revenue Share (%) by Sector, 2011

Figure 7.1 QIAGEN: Historical Revenue (\$m), Net Income (\$m) and Profit Margin (%), 2007-2011

Figure 7.2 QIAGEN: Revenues (\$bn) by Customer Class, 2011

Figure 7.3 QIAGEN: Revenue Shares (%) by Customer Class, 2011

Figure 7.4 QIAGEN: Revenue Shares (%) by Region, 2011

Figure 7.5 QIAGEN: Historical R&D Expense (\$m) and R&D Expense as a Percentage of Net Revenue (%), 2007-2011

Figure 7.6 Roche: Revenues (\$bn) by Sector, 2011

Figure 7.7 Roche: Revenue Shares (%) by Sector, 2011

Figure 7.8 Roche Diagnostics: Revenue Shares (%) by Region, 2011

Figure 7.9 Roche Diagnostics: Revenues (\$bn) by Sector, 2011

Figure 7.10 Roche Diagnostics: Revenue Shares (%) by Sector, 2011

Figure 7.11 Dako: Revenue (\$bn) by Sector, 2011

Figure 7.12 Dako: Revenue Shares (%) by Sector, 2011

Figure 7.13 Dako: Revenue (\$bn) by Region, 2011

Figure 7.14 Dako: Revenue Shares (%) by Region, 2011

Figure 7.15 bioMerieux: Revenue (\$m) by Sector, 2011

Figure 7.16 bioMerieux: Revenue Share (%) by Sector, 2011

Figure 7.17 bioMerieux: Clinical Applications Revenue (\$m) by Sector, 2011

Figure 7.18 bioMerieux: Clinical Applications Revenue Shares (%) by Sector, 2011

Figure 7.19 Siemens: Revenues (\$bn) by Sector, 2011

Figure 7.20 Siemens: Revenue Shares (%) by Sector, 2011

Figure 7.21 Siemens: Revenue Shares (%) by Region, 2011

Figure 7.22 Siemens Healthcare: Revenue Shares (%) by Region, 2011

Figure 7.23 MDxHealth: Revenues (\$m) by Reporting Segment, 2011

Figure 7.24 MDxHealth: Revenue Shares (%) by Reporting Segments

Figure 8.1 China's Historical Healthcare Expenditure (\$bn), 2001-2010

Figure 10.1 Companion Diagnostics Market: World Sales Forecast (\$bn), 2011, 2016, 2018 and 2023

Figure 10.2 Projected Market Size (\$bn): Theranostics, Other Companion Diagnostics and Total Companion Diagnostics Market in 2011, 2016, 2018 and 2023

COMPANIES LISTED

Abbott

Alere

ARCA Biopharma

ARGENE

AstraZeneca

Bayer

Beckman Coulter

BioMarin Pharmaceutical

bioMerieux

Biocartis

Biomonitor

Boehringer Ingelheim

Brain Resource Company

Bristol-Myers Squibb

CancerGuide Diagnostics

Caprion Proteomics

Caris Life Sciences

Celldex Therapeutics

Cellestis

Cephalon
Cepheid
Clearstone Central Laboratories
Clinical Reference Laboratory
CompanDX
Compendia Bioscience
Crescendo Bioscience
Curidium Medica
Dako
DiagnoCure
DxS
Eli Lilly
Endocyte
Epitomics
Exosome Diagnostics
Explera
Flagship Biosciences
Foundation Medicine
Genfit
GenMark Diagnostics
Genomic Health
Genzyme Genetics
GlaxoSmithKline
HistologiX
Hologic
Ibis Biosciences
InDex Pharmaceuticals
Invivoscribe Technologies
Ipsen
Ipsogen
Johnson and Johnson
Knome
Lab21
LabCorp
Laboratory for Personalized Molecular Medicine
Life Technologies
MDxHealth
Medco Health Sciences
Merck

MolecularMD
Monogram Biosciences
Myriad Genetics
Nanosphere
Navigenics
Oncomed
Opko Health
Oxford BioTherapeutics
Pfizer
PharmaMar
Progenika Biopharma
Prometheus
QIAGEN
Quest Diagnostics
Quintiles Transnational Corporation
Randox Pharma Services
RiboMed Biotechnologies
Roche
SABioscience Corporation
Saladax Biomedical
Siemens
Signal Genetics
Sirius Genomics
Skyline Diagnostics
STARLIMS Technologies
SterilMed
Synthes
Takeda
Target Discovery
TcLand Expression
Theranostics (NZ)
Theranostics Health
TIB MolBiol
Tocagen
Tragara Pharmaceuticals
Transgene
Transgenomic
TrimGen Corporation
Unilabs

ViiV Healthcare
Weisenthal Cancer Group
Zinfandel

GOVERNMENT AGENCIES AND OTHER ORGANISATIONS MENTIONED IN THIS REPORT

FDA
EMA
GHTF
IMDRF
Ministry of Health of the People's Republic of China
UN
WHO

I would like to order

Product name: Top Companion Diagnostic Companies: Competitive Analysis 2013-2023

Product link: <https://marketpublishers.com/r/TEA190D8F77EN.html>

Price: US\$ 2,401.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TEA190D8F77EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970